3Department of Biology, Stanford University, Stanford, California. 5Cancer Biology Program, Stanford University School of Medicine, Stanford, California. 12Chan Zuckerberg Biohub, San Francisco, ...
1Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational ...
Abstract. AZD9833 is a potent, orally delivered, non-steroidal selective estrogen receptor degrader (SERD) that both antagonizes and degrades ERα. It is currently in clinical testing for the treatment ...
1Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California. 2Cancer Institute, Stanford University School of Medicine, Stanford, ...
Cancer Discov (2026) 16 (1): OF1.
SEMA3G binding to NRP1 suppresses cytotoxic T-cell activity to induce an immunosuppressive tumor microenvironment, positioning SEMA3G as a promising therapeutic target for improving cancer ...
1Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Centre of Montpellier, Montpellier, France.
1Yonsei University, College of Medicine, Seoul, Republic of Korea.
1Department of Oncology, University of Lausanne, Lausanne, Switzerland.
1Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, ...
1Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany. 2University of Tübingen, Tübingen, Germany.
1The Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, Houston, Texas. *Corresponding Author: Mikhail G Kolonin, Institute of Molecular Medicine, The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback